Related Experiment Video
Updated: Feb 25, 2026
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
ARRDC3 Inhibits the Progression of Human Prostate Cancer Through ARRDC3-ITGβ4 Pathway
1Guangdong Provincial Institute of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515. China.
Background:
Arrestin domain-containing protein 3 (ARRDC3) is a member of the mammalian α-arrestins family, which has been identified as a tumor suppressor gene in human breast cancer, but its functions are still not clear in human prostate cancer (PCa).
Objective:
The purpose of the present study was to investigate clinical significance, biological functions and underlying mechanisms of ARRDC3 deregulation in PCa.
Method:
Involvement of ARRDC3 deregulation in malignant phenotypes of PCa was demonstrated by clinical sample evaluation, microarray analysis, and in vitro and in vivo experiments. The mechanisms underlying its regulatory effect on tumor progression were determined.
Results:
Microarray analysis found that ARRDC3 low expression was significantly associated with high Gleason score in TMA, and the expression level of ARRDC3 was negatively correlated with Gleason score, metastasis and biochemical recurrence in online Taylor Dataset. As revealed by the dataset, Kaplan-Meier analyses revealed that the biochemical recurrence-free survival (BCR-free) time of PCa patients with ARRDC3 high expression was longer than those with ARRDC3 low expression. Additionally, both univariate and multivariate analyses showed that the downregulation of ARRDC3 was an independent prognostic marker for BCR-free survival of patients with PCa. In vitro studies revealed that ARRDC3 could inhibit proliferation, migration and invasion of PCa cell lines. In vivo studies proved that ARRDC3 over-expressing cells formed significantly larger tumor nodules and remarkably speeded up tumor xenografts growth compared with the controls. Moreover, immunohistochemical scores of Ki67 and MMP-9 were significantly lower than those of the control group. Finally, correlation analysis indicated that the expression of ARRDC3 was negatively correlated with ITGβ4 in clinical PCa tissues and cell lines.
Conclusion:
Our data revealed that ARRDC3 can serve as a tumor suppressor to inhibit PCa progression and an independent marker to predict the risk of biochemical recurrence and metastasis after radical resection of PCa.
Insights
Arrestin domain-containing protein 3 (ARRDC3) acts as a tumor suppressor in prostate cancer (PCa), inhibiting progression and metastasis. Low ARRDC3 expression predicts higher recurrence risk, making it a valuable prognostic marker for PCa patients.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Arrestin domain-containing protein 3 (ARRDC3), a mammalian α-arrestin, is a known tumor suppressor in breast cancer.
- Its specific role and mechanisms in prostate cancer (PCa) remain largely uncharacterized.
Purpose of the Study:
- To elucidate the clinical significance and biological functions of ARRDC3 deregulation in PCa.
- To investigate the underlying mechanisms by which ARRDC3 influences PCa progression.
Main Methods:
- Clinical sample evaluation and microarray analysis were employed.
- In vitro and in vivo experiments assessed ARRDC3's impact on PCa cell lines and tumor growth.
- Correlation analyses identified potential molecular interactions.
Main Results:
- Low ARRDC3 expression correlated with higher Gleason scores, metastasis, and biochemical recurrence in PCa.
- ARRDC3 downregulation independently predicted shorter biochemical recurrence-free survival.
- In vitro and in vivo studies demonstrated ARRDC3's inhibitory effect on PCa cell proliferation, migration, invasion, and tumor growth.
- ARRDC3 expression negatively correlated with ITGβ4.
Conclusions:
- ARRDC3 functions as a tumor suppressor, inhibiting PCa progression.
- ARRDC3 serves as an independent prognostic marker for predicting biochemical recurrence and metastasis risk post-surgery.
Related Concept Videos
02:34Inhibition of Cdk Activity
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:22PI3K/mTOR/AKT Signaling Pathway
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...